We urgently need new antibiotics against the most devastating Gram-negative infections. Nevertheless, bringing new classes of antibiotics against them to the clinics has been a huge challenge.
I am very happy that Thomas Clairfeuille from Roche will visit us for a @LED3hub Lecture on March 26th to talk about one of the recent success stories in the field: Zosurabalpin, which targets the LPS transport. (1/2)

